RT Journal Article
SR Electronic
T1 Tobacco, nicotine, and cannabis use and exposure in an Australian Indigenous population during pregnancy: A protocol to measure parental and foetal exposure and outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.29.24303540
DO 10.1101/2024.02.29.24303540
A1 Ratsch, Angela
A1 Burmeister, Elizabeth A.
A1 Bird, Aunty Veronica
A1 Bonner, Aunty Joyce
A1 Miller, Uncle Glen
A1 Speedy, Aunty Marj
A1 Douglas, Graham
A1 Ober, Stevan
A1 Woolcock, Ann
A1 Blair (nee Murdoch), Sharly
A1 Weng, Min-Tz
A1 Miles, Jared A.
A1 Steadman, Kathryn J.
YR 2024
UL http://medrxiv.org/content/early/2024/03/04/2024.02.29.24303540.abstract
AB Background The Australian National Perinatal Data Collection collates all live and stillbirths from States and Territories in Australia. In that database, maternal cigarette smoking is noted twice (smoking <20 weeks gestation; smoking >20 weeks gestation). Cannabis use and other forms of nicotine use, for example vaping and nicotine replacement therapy, are nor reported. The 2021 report shows the rate of smoking for Australian Indigenous mothers was 42% compared with 11% for Australian non-Indigenous mothers. Evidence shows that Indigenous babies exposed to maternal smoking have a higher rate of adverse outcomes compared to non-Indigenous babies exposed to maternal smoking.Objectives The reasons for the differences in health outcome between Indigenous and non-Indigenous pregnancies exposed to tobacco and nicotine is unknown but will be explored in this project through a number of activities. Firstly, the patterns of parental and household tobacco, nicotine and cannabis use and exposure will be mapped during pregnancy. Secondly, a range of biological samples will be collected to enable the first determination of Australian Indigenous people’s nicotine and cannabis metabolism during pregnancy; this assessment will be informed by pharmacogenomic analysis. Thirdly, the pharmacokinetic and pharmacogenomic findings will be considered against maternal, placental, foetal and neonatal outcomes. Lastly, an assessment of population health literacy and risk perception related to tobacco, nicotine and cannabis products peri-pregnancy will be undertaken.Methods This is a community-driven, co-designed, prospective, mixed-method observational study with regional Queensland parents expecting an Australian Indigenous baby and their close house-hold contacts during the peri-gestational period. The research utilises a multi-pronged and multi-disciplinary approach to explore interlinked objectives.Results A sample of 80 mothers expecting an Australian Indigenous baby will be recruited. This sample size will allow estimation of at least 90% sensitivity and specificity for the screening tool which maps the patterns of tobacco and nicotine use and exposure versus urinary cotinine with 95% CI within ±7% of the point estimate. The sample size required for other aspects of the research is less (pharmacokinetic and genomic n=50, and the placental aspects n=40), however from all 80 mothers, all samples will be collected.Conclusions Results will be reported using the STROBE guidelines for observational studies.Forward We acknowledge the Traditional Custodians, the Butchulla people, of the lands and waters upon which this research is conducted. We acknowledge their continuing connections to country and pay our respects to Elders past, present and emerging.Notation: In this document, the terms Aboriginal and Torres Strait Islander and Indigenous are used interchangeably for Australia’s First Nations People. No disrespect is intended, and we acknowledge the rich cultural diversity of the groups of peoples that are the Traditional Custodians of the land with which they identify and with whom they share a connection and ancestry.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MetroNorth HHS (HREC/2021/QRBW/77758) and the University of Queensland (2021/HE002069)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.AbbreviationsADHDattention-deficit/hyperactivity disorderCOcarbon monoxideDAGsdirected acyclic graphsmRNAmessenger ribonucleic acidnAChRnicotinic acetylcholine receptorsNMRnicotine metabolite ratioNRTnicotine replacement therapyPOCpoint of careQAIHCQueensland Aboriginal and Torres Strait Islander Health CouncilNOTICERatsch Assessment of Tobacco and NicotineSIDSsudden infant death syndromeSNPssingle nucleotide polymorphismsTNEtotal nicotine equivalents